What’s Driving Growth in the Cerebral Adrenoleukodystrophy (CALD) Market? Insights into Key Trends and Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the cerebral adrenoleukodystrophy (cald) market grown in recent years?
The market for cerebral adrenoleukodystrophy (CALD) has seen swift expansion in the most recent years, with its size projected to rise from $6.58 billion in 2024 to $7.56 billion in 2025, achieving a compound annual growth rate (CAGR) of 14.9%. The significant growth observed in the historic period can be traced back to the increased awareness around uncommon diseases, enhanced screening procedures for newborns, a burgeoning emphasis on neurodegenerative disorders, the introduction of Lorenzo’s oil, research endeavors concerning peroxisomal disorders, advocacy initiatives by patient assistance groups, and advancements in healthcare infrastructure.
How is the cerebral adrenoleukodystrophy (cald) market size expected to evolve during the forecast period?
Anticipated to experience swift expansion in the upcoming years, the cerebral adrenoleukodystrophy (CALD) market is projected to reach $13.05 billion in 2029, with a compound annual growth rate (CAGR) of 14.6%. The predicted growth can be attributed to factors such as the emergence of gene therapy, advances in newborn screening technologies, evolution in targeted drug delivery systems, growth in rare disease research investments, increased utilization of digital health tools, and a rising demand for personalized treatments. Further contributing factors include collaborations between biotech and pharmaceutical companies, and greater public awareness achieved through international advocacy campaigns. The forecast period will also witness certain trends such as gene editing via clustered regularly interspaced short palindromic repeats (CRISPR), Artificial Intelligence-empowered diagnostic algorithms, advanced neuroimaging techniques, advancements in next-generation sequencing, brain-focused nanomedicine, neurological monitoring wearable devices, digital twin simulations for treatment planning, cloud-based genomic data sharing, virtual reality for caregiver training, and blockchains for secure patient data management.
Get your cerebral adrenoleukodystrophy (cald) market report here!
Which key drivers are propelling the cerebral adrenoleukodystrophy (cald) market’s growth?
The cerebral adrenoleukodystrophy (CALD) market is forecasted to expand due to the increasing healthcare expenditure. The rise in healthcare spending can be ascribed to the growing ageing population, persistent diseases, advancements in medicine, escalating drug costs, and wider health coverage. Such spending aids CALD through the enhancement of diagnostic tools, sponsoring novel treatments, such as gene therapy and stem cell transplantation, and bettering patient access to dedicated care and early intervention. For example, as reported by the US-based Centers for Medicare and Medicaid Services (CMS), the national health expenditures (NHE) increased by 7.5% in 2023, surpassing the gross domestic product (GDP) growth of 6.1% in December 2024. From 2023 to 2032, the average annual growth rate of NHE is anticipated to be 5.6%, thereby increasing the health expenditure portion of the GDP from 17.3% in 2022 to 19.7% in 2032. As such, the burgeoning healthcare spending is contributing to the growth of the cerebral adrenoleukodystrophy (CALD) market.
What are the market segments in the cerebral adrenoleukodystrophy (cald) industry?
The cerebral adrenoleukodystrophy (CALD) market covered in this report is segmented –
1) By Type Of Treatment: Dietary Management, Medications, Stem Cell Therapy
2) By Patient Age Group: Adults, Children, Infants, Teens
3) By End User: Healthcare Facilities, Patients And Caregivers, Pharmaceutical Companies
Subsegments:
1) By Dietary Management: Lorenzo’s Oil, Omega-3 Fatty Acids, Fatty Acid Supplements
2) By Medications: Corticosteroids, Antioxidants, Anti-inflammatory Drugs
3) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (HSCT), Gene Therapy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21135&type=smp
Which leading companies are shaping the growth of the cerebral adrenoleukodystrophy (cald) market?
Major companies operating in the cerebral adrenoleukodystrophy (CALD) market are Pfizer Inc., Sanofi S.A., Novartis AG, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Poxel S.A., Neuraxpharm Group, Viking Therapeutics Inc., MedDay Pharmaceuticals SAS, Calico Life Sciences, Magenta Therapeutics Inc., SOM Biotech, Minoryx Therapeutics S.L., NeuroVia Inc., SwanBio Therapeutics Inc., Autobahn Therapeutics Inc., Bluebird Bio Inc., Orpheris Inc., Sperogenix Therapeutics, Abliva
What key trends are currently impacting the cerebral adrenoleukodystrophy (cald) market’s development?
Key players in the cerebral adrenoleukdystrophy (CALD) market are focusing on the creation of advanced therapies, such as gene therapies, with the aim of introducing long-term and more effective solutions to halt disease progression, enhance patient results, and potentially provide curative treatments for this serious and life-threatening disease. At the heart of gene therapy lies the alteration or replacement of malfunctioning genes in a patient’s cells to treat, or even eradicate diseases. For example, in September 2022, Bluebird Bio Inc., an American biotechnological enterprise, obtained expedited approval from United States Food and Drug Administration (FDA) for Skysona (elivaldogene autotemcel), aimed at slowing budding neurologic dysfunction in boys aged 4-17 with early, active CALD. Skysona is a one-time gene therapy that utilises ex vivo transduction with the Lenti-D lentiviral vector (LVV) to inject functional ABCD1 gene versions into a patient’s hematopoietic stem cells (HSCs). This additional gene enables patients to generate the ALD protein (ALDP), which can then engage in the local breakdown of very long-chain fatty acids (VLCFAs), a process which is thought to slow or even halt further inflammation and demyelination.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21135
Which geographic areas are influencing the growth of the cerebral adrenoleukodystrophy (cald) market?
North America was the largest region in the cerebral adrenoleukodystrophy (CALD) market in 2024. The regions covered in the cerebral adrenoleukodystrophy (CALD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Convalescent Plasma Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report
Plasma Fractionation Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report
Breast Cancer Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
